These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25921042)

  • 1. Placebo studies should not be undertaken in NMO--Yes.
    Palace J
    Mult Scler; 2015 May; 21(6):689-91. PubMed ID: 25921042
    [No Abstract]   [Full Text] [Related]  

  • 2. Placebo studies should not be undertaken in NMO--No.
    Greenberg BM
    Mult Scler; 2015 May; 21(6):691-3. PubMed ID: 25921044
    [No Abstract]   [Full Text] [Related]  

  • 3. Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary.
    Weinshenker BG
    Mult Scler; 2015 May; 21(6):693-4. PubMed ID: 25921043
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges and opportunities in designing clinical trials for neuromyelitis optica.
    Weinshenker BG; Barron G; Behne JM; Bennett JL; Chin PS; Cree BA; de Seze J; Flor A; Fujihara K; Greenberg B; Higashi S; Holt W; Khan O; Knappertz V; Levy M; Melia AT; Palace J; Smith TJ; Sormani MP; Van Herle K; VanMeter S; Villoslada P; Walton MK; Wasiewski W; Wingerchuk DM; Yeaman MR;
    Neurology; 2015 Apr; 84(17):1805-15. PubMed ID: 25841026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo controls in clinical trials of new therapies for osteoporosis.
    Levine RJ
    J Bone Miner Res; 2003 Jun; 18(6):1154-9. PubMed ID: 12817775
    [No Abstract]   [Full Text] [Related]  

  • 6. Exploring the use of the sham design for interventional trials: implications for endoscopic research.
    Wilcox CM
    Gastrointest Endosc; 2008 Jan; 67(1):123-7. PubMed ID: 18155434
    [No Abstract]   [Full Text] [Related]  

  • 7. The ethics of placebo controlled clinical trials in NMO - A balance of risks.
    Levy M
    Mult Scler Relat Disord; 2015 Nov; 4(6):512-4. PubMed ID: 26590656
    [No Abstract]   [Full Text] [Related]  

  • 8. Placebo controlled trials in neuromyelitis optica are needed and ethical.
    Cree BA
    Mult Scler Relat Disord; 2015 Nov; 4(6):536-45. PubMed ID: 26590660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid exacerbation of neuromyelitis optica after rituximab treatment.
    Dai Y; Lu T; Wang Y; Fang L; Li R; Kermode AG; Qiu W
    J Clin Neurosci; 2016 Apr; 26():168-70. PubMed ID: 26704780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
    Ciron J; Audoin B; Bourre B; Brassat D; Durand-Dubief F; Laplaud D; Maillart E; Papeix C; Vukusic S; Zephir H; Marignier R; Collongues N;
    Rev Neurol (Paris); 2018 Apr; 174(4):255-264. PubMed ID: 29606320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Topics of neuromyelitis optica].
    Miyamoto K
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):468-74. PubMed ID: 25748131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromyelitis optica: association with paroxysmal painful tonic spasms.
    Carnero Contentti E; Leguizamón F; Hryb JP; Celso J; Pace JL; Ferrari J; Knorre E; Perassolo MB
    Neurologia; 2016 Oct; 31(8):511-5. PubMed ID: 25655945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of tocilizumab, an antibody against interleukin-6 receptor, for the treatment of neuromyelitis optica].
    Yamamura T; Araki M
    Brain Nerve; 2014 Oct; 66(10):1159-65. PubMed ID: 25296870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network.
    Turner D; Koletzko S; Griffiths AM; Hyams J; Dubinsky M; de Ridder L; Escher J; Lionetti P; Cucchiara S; Lentze MJ; Koletzko B; van Rheenen P; Russell RK; Mack D; Veereman G; Vermeire S; Ruemmele F
    J Pediatr Gastroenterol Nutr; 2016 Jan; 62(1):183-7. PubMed ID: 26545204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
    Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
    Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of neuromyelitis optica].
    Nielsen HH; Ravnborg M; Illes Z
    Ugeskr Laeger; 2014 Jun; 176(26):V02130104. PubMed ID: 25294570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
    Kitley J; Evangelou N; Küker W; Jacob A; Leite MI; Palace J
    J Neurol Sci; 2014 Apr; 339(1-2):223-5. PubMed ID: 24576801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for trials without placebo controls in pre-IDDM?
    Mauricio D; de Leiva A
    Diabetes Metab Rev; 1997 Dec; 13(4):319-20. PubMed ID: 9509285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.